MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Alzheimers & Dementia
Voyager Therapeutics, Inc. (NASDAQ: VYGR)*
Organization & Developments: Voyager Therapeutics
Parents
Voyager Therapeutics, Inc. (NASDAQ: VYGR)*
Children
*Gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS)
2014: Third Rock’s Voyager Hunts For CNS Disorders With Gene Therapy
2017: Voyager Therapeutics: Parkinson's Data Excites Wall Street - Voyager Therapeutics (NASDAQ:VYGR)
2018: Voyager Therapeutics inks deal with AbbVie to develop anti-tau antibodies in neurodegenerative diseases_seekingalpha.com
2018: Voyager Therapeutics Stock Rises On AbbVie Deal In Alzheimer's Disease
2020: Voyager shares take a hit as FDA slaps a hold on the IND for Huntington’s gene therapy
2021: Neurocrine Terminates Parkinson's Deal with Voyager Following Clinical Hold
2021: Voyager Therapeutics: Complicated Story In Gene Therapy Development
2022: Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target_ voyagertherapeutics
2023: Voyager Therapeutics' Strategic Partnerships And TRACER Technology - Speculative Buy_ seekingalpha.com
2023: Voyager: Recent Neurocrine Deal Signals More Upside_seekingalpha.com
2024: Novartis ignites new stage of Voyager pact with $15M capsid deal
2024: Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
2024: Voyager Advances Collaboration with Neurocrine; Third Gene
2024: Voyager Selects Tau Silencing Gene Therapy Development
2024: Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
2024: Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
2024: Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
2024: Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
2024: Voyager Therapeutics: On Track To Deliver High Returns On Investment
2024: Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral_seekingalpha.com
2024: Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects
2025: H.C. Wainwright maintains $30 target on Voyager Therapeutics stock Investing.com
2025: New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
2025: Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)
2025: Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
2026: Voyager Therapeutics (VYGR): 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Jumps
*Key People: Voyager Therapeutics
Finance & Acquisitions: Voyager Therapeutics